You do not have permission to access this chart.
Please Sign Up or Login
News for Genetron Holdings Limited (GTH)
58 minutes ago |

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a partnership agreement with dMed Biopharmaceutical for new drug research and development in the field of oncology. The company was founded in 2015 and is headquartered in Beijing, the People’s Republic of China.




Diagnostics & Research


Genetron Holdings Limited Building 11 1-2 Floors Zone 1, No. 8 Life Science Parkway Changping District Beijing 102206 China



86 10 5090 7500

Leave a comment

Your email address will not be published. Required fields are marked *